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Neurodegenerative monogenic diseases often affect tissues and organs beyond the
nervous system. An effective treatment would require a systemic approach. The intra-
venous administration of novel therapies is ideal but is hampered by the inability of
such drugs to cross the blood–brain barrier (BBB) and precludes efﬁcacy in the central
nervous system. A number of these early lethal intractable diseases also present
devastating irreversible pathology at birth or soon after. Therefore, any therapy would
ideally be administered during the perinatal period to prevent, stop, or ameliorate disease
progression.The concept of perinatal gene therapy has moved a step further toward being
a feasible approach to treating such disorders.This has primarily been driven by the recent
discoveries that particular serotypes of adeno-associated virus (AAV) gene delivery vectors
have the ability to cross the BBB following intravenous administration. Furthermore, safety
has been demonstrated after perinatal administration mice and non-human primates. This
review focuses on the progress made in using AAV to achieve systemic transduction and
what this means for developing perinatal gene therapy for early lethal neurodegenerative
diseases.
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INTRODUCTION
The development of intravenously administered therapies for
neurodegenerative diseases is often impeded by the blood–brain
barrier (BBB). The BBB isolates and protects the central ner-
vous system (CNS) by restricting large or hydrophobic molecules
such as viruses and large proteins from crossing into the CNS
(Rubin and Staddon,1999). Remarkable efﬁcacy has been reported
in clinical trials for neurodegenerative disorders using ex vivo
hematopoietic stem cell gene therapy (Cartier et al., 2009; Bifﬁ
et al., 2013). While this approach is hugely promising for those
diseases where secretion of a soluble protein from bone marrow
derived microglia and therapeutic recapture from neighboring
neural cells is possible, other conditions may not be amenable
to this approach. Therefore, highly efﬁcient and direct delivery of
genes, ideally targeted to speciﬁc neural cells using cell type spe-
ciﬁc promoters, would be required. The adeno-associated virus
(AAV) vector system has been subject to recent, intense, scrutiny
due to: (1) high efﬁciency of neural cell transduction (Gray et al.,
2011); (2) excellent safety proﬁle in humans (Nakai et al., 2005);
(3) low toxicity (Daya and Berns, 2008); and (4) lack of inte-
gration into the host genome, therefore imposing a lower risk of
insertional oncogenesis associated with integrating vectors such as
lentivirus (Themis et al., 2005;Howe et al., 2008). The post-mitotic
status of neurons makes them a good target for non-integrating
vectors. Thus, AAV is now a commonly used vector for clinical
trials addressing neurological disease. This must be balanced with
speciﬁc disadvantages associated with AAV vectors: (1) a limited
packaging capacity of around 4.7 kb (Dong et al., 2010) and (2)
the possibility of pre-existing humoral response to capsid protein
because of prior wild-type AAV infections (Boutin et al., 2010).
Numerous AAV serotypes have been isolated from human and
non-human primates (NHPs). Their tropisms following intra-
venous administration have been studied in mice and NHPs, these
include AAV6, 6.2, 7, 8, 9, rh.8, rh.10, rh.39, and rh.43 (Towne
et al., 2008; Zincarelli et al., 2008; Gray et al., 2011; Yang et al.,
2014). Interestingly, AAV9 has been shown to cross the BBB in
adult and neonatal animals following intravenous infusion of the
virus (Zincarelli et al., 2008; Duque et al., 2009; Foust et al., 2009;
Fu et al., 2011). Other AAV serotypes have since demonstrated the
ability to cross the BBB in neonatal mice following intravenous
administrationwithAAVrh.10 andAAVrh.8 both showingpromise
(Zhang et al., 2011).
An example of a lethal neurodegenerative monogenic disease
with visceral involvement is neuronopathic Gaucher disease (GD).
Patients exhibit hepatomegaly and splenomegaly in addition to
the ultimately lethal brain pathology (Gupta et al., 2011). Enzyme
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replacement therapy (ERT) has been highly successful in treating
the visceral pathology associated to GD (Cox, 2013) and other
lysosomal storage disorders (Ortolano et al., 2014). However, the
presence of the BBB has severely restricted recombinant enzyme
from crossing into the CNS and rendering ERT ineffective in pre-
ventingdeath fromneurodegeneration (Pastores et al., 1993;Wynn
et al., 2009). Such systemic diseases will ideally require a systemic
treatment. AAV serotypes that can be intravenously administered
and cross the BBB raises hope that this approach may have clinical
potential for treating such disorders. Furthermore, the prospect of
administering gene therapy during the perinatal period is attrac-
tive for a number of reasons. Here we discuss the potential of AAV
administered during the perinatal period to treat systemic disor-
ders, with an emphasis upon neurodegenerative conditions, using
a selection of studies from a rapidly growing ﬁeld to highlight
progress.
PERINATAL GENE DELIVERY
Gene delivery to the developing fetus or neonate has been dis-
cussed extensively over the years (David and Peebles, 2008; Rahim
et al., 2010; Buckley et al., 2011; Coutelle and Waddington, 2012;
Mattar et al., 2012; Roybal et al., 2012). While this is yet to be real-
ized in the clinic, the advantages that such an approach offers are
appealing (1) A higher vector to cell ratio enhancing the efﬁciency
of gene delivery, (2) A naïve immune system allows for the induc-
tion of ‘tolerance’ to vector-mediated expression of a protein that
the body may not recognize as self, (3) Reduced chances of an
immune response to a viral vector since the fetus is unlikely to
have had previous viral infections, (4) Potentially enhanced access
of vectors to progenitor and stem cell niches, and (5) The ability
to prevent pathology from manifesting – arguably most impor-
tant in the context of acute neurodegenerative disorders where
susceptible post-mitotic neurons must be protected at the earli-
est possible moment to prevent irrevocable loss. The arguments
in favor of in utero gene therapy must be balanced with those
against such as (1) Is there an established method for early diag-
nosis for the disease in question? (2) If the fetus is diagnosed with
an intractable genetic disorder then would the mother opt to ter-
minate the pregnancy? We refer the reader to a separate elegant
review by Coutelle and Ashcroft (2012) that discusses the ethical,
legal and societal implications. (3) Fetal developmental and cell
physiological abnormalities caused by overexpression of the thera-
peutic transgene. Realistically, gene therapy for the neonate will be
developed ﬁrst. Symptoms may be more obvious; further investi-
gation by newborn screening programs or scans may facilitate and
conﬁrm diagnosis followed by administration of gene therapy –
but in many cases of acute and aggressive neurodegenerative dis-
orders that present during gestation, neonatal intervention could
already be too late.
AAV IN FETAL AND NEONATAL RODENTS
Very few studies have examined systemic gene delivery via intra-
venous administration to the fetal rodent. This is probably due
to the technical expertise required to perform this procedure.
Rahim et al. (2011) described extensive reporter gene expres-
sion in mice following in utero intravenous injection of AAV9.
This vector efﬁciently crossed the BBB and mediated global gene
expression throughout the nervous system. More studies have
examined gene delivery following intravenous administration of
AAV into neonatal rodents. Foust et al. (2009) showed that intra-
venous injections of AAV9 carrying the GFP reporter gene into
neonatal mice resulted in extensive transduction of neuronal cells
within the spinal cord and the brain and within the heart and
skeletal muscles. Similarly, Duque et al. (2009) showed efﬁcient
transduction of motor neurons within the spinal cords of adult
mice and cats after intravenous injections of AAV9. Foust et al.
(2009) further elaborated on their previous AAV9 study by res-
cuing an early lethal mouse model of spinal muscular atrophy
(SMA). Remarkably, a single intravenous injection at birth of
AAV9 carrying the SMN gene was sufﬁcient to correct the neu-
romuscular electrophysiology and motor functions (Foust et al.,
2010). In contrast, injection of therapeutic AAV9 vector at later
time points (5 and 10 days after birth) produced partial correction
or little effect, respectively. This highlights the critical importance
of identifying the therapeutic window of opportunity that may
be narrow and early in development. Towne et al. (2008) demon-
strated motor neuronal transduction within the spinal cord and
the brain stem through intravenous administration of AAV6 to
adult mice. AAV8, 9, and rh.10 also achieved impressive nervous
system transduction (Yang et al., 2014). This also supports the
observations of impressive neuronal and glial transduction in a
separate study using AAV9 in adult mice (Gray et al., 2011). Fur-
thermore, a systematic comparisonof variousAAVserotypes in the
neonatal mouse revealed thatAAV9 was highly efﬁcient in crossing
the BBB, although AAVrh.10 also holds great promise and must be
investigated further (Zhang et al., 2011). To date, given the larger
body of evidence and data on systemic delivery, the review will
focus on AAV9.
The timing of systemic administration of AAV9 is also impor-
tant in the context of gene expression in particular neural cells.
Foust et al. (2009) demonstrated that AAV9 carrying the GFP
gene driven by the chicken beta actin hybrid promoter effectively
transduces neurons when intravenously administered to neonatal
mice. However, expression becomes preferentially astrocyte spe-
ciﬁc when administered to adult mice. Further analysis revealed
that this ‘switch’ between expression in cell types occurs within
the ﬁrst 10 days of life (Foust et al., 2010). Rahim et al. (2011)
reported that intravenous injection of AAV9 carrying theGFP gene
driven by the CMV promoter to E15 fetal mice led to preferen-
tial neuronal expression and minimal astrocyte expression. When
the same vector was administered to P1 neonatal mice, preferen-
tial astrocyte expression was observed. In some cases, expression
throughout the nervous system may not be required and prefer-
ably targeted to a speciﬁc neuronal population. This reﬁnement
in targeted gene expression will require more work in identifying
suitable promoters or microRNA sequences.
AAV IN FETAL AND NEONATAL NON-HUMAN PRIMATES
Non-human primates are a valuable pre-clinical model given the
signiﬁcant difference between fetal and neonatal development and
cell type expression in rodents and humans. Mattar et al. (2013)
evaluated the ability of AAV9 to transduce the CNS through a sin-
gle intravenous injection into a late gestation fetal macaque. The
administration of the virus was conducted using an established
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ultrasound guided clinical protocol that is routinely used world-
wide. Examination of administered animals at 6 and 14 days of age
revealed signiﬁcant neuron transduction in the CNS and the PNS,
with a lower efﬁciency seen in astrocytes. Furthermore, signiﬁcant
transduction in the skeletal muscle, heart and liver was observed.
This work supports the ﬁndings of Rahim et al. (2011) in fetal
mice intravenously administered with AAV9. However, the poten-
tial differences between mouse and NHPs were highlighted by
Bevan et al. (2011) who intravenously administered AAV9 carry-
ing the GFP gene driven by the chicken beta actin hybrid promoter
to NHPs at P1, P30, and P90. Monkeys that received vector at
P1 showed mostly astrocyte and microglial targeting in the brain
that is in contrast to mice that received the same vector at P1
and demonstrated predominantly neuronal transduction (Foust
et al., 2010). Bevan et al. (2011) attribute this discrepancy to dif-
ferences in the timing of gliogenesis between the two species. The
same study also reported sustained expression in the musculature
and liver of injected monkeys. Table 1 summarizes the key fea-
tures described above. Intravenous injection of the vector used by
Bevan et al. (2011) has also been administered to older 3–4 year
old rhesusmacaques (Bevan et al., 2011; Gray et al., 2011). 4-weeks
after injection, analysis showed similar gene expression proﬁles –
again predominantly glial in the brain with extensive transduc-
tion of the musculature and liver. Interestingly, monkeys that were
serotype positive for AAV9 and had pre-existing circulating AAV9
neutralizing antibodies exhibited signiﬁcantly reduced levels of
transduction (Gray et al., 2011). This issue will be further dis-
cussed later but represents a strong argument for administering
during the perinatal period where the subject is less likely to have
been exposed to AAV infection and more likely to be serotype
negative.
CLINICAL TRANSLATION OF SYSTEMIC AAV-MEDIATED
GENE THERAPY
Systemic delivery of AAV vectors in patients has already been
demonstrated in a recent successful clinical trial using AAV8 to
express the FIX gene to treat patients with the blood clotting
disorder hemophilia B (Nathwani et al., 2011). AAV8 carrying
the FIX gene driven by the LP1 liver speciﬁc promoter was
administered, intravenously, to six patients with severe hemophilia
B all over the age of 18 years old. Four of the six patients did
not require prophylactic recombinant FIX. The other two patients
that received a higher dose of vector either developed an AAV8-
capsid speciﬁc T cell response or a small increase in liver enzyme
levels – both symptoms were treated using glucocorticoids (Nath-
wani et al., 2011). While this study is in older patients, it provides
an important proof-of-principle; high doses of AAV can be intra-
venously administered and tolerated without any life-threatening
adverse effects. Furthermore, a Phase I clinical trial for the neu-
romuscular condition SMA is currently recruiting patients less
than 9 months old (ClinicalTrials.gov Identiﬁer: NCT02122952).
Patients will receive an intravenous infusion of AAV9 carrying
the therapeutic SMN gene driven by the CMV enhancer/chicken-
beta-actin promoter. Interestingly, an inclusion criteria is onset
of disease at birth to 6 months of age and patients are eligi-
ble to be included if they are 9 months or younger at time of
infusion. The young age of the potential participants exempli-
ﬁes the volition to intervene as early as possible and vindicates
a strategy to treat diseases that may manifest at birth. This trial
will also address potential logistical and immunological barri-
ers that have been proposed to impede such an approach. It
has been suggested that this approach for using AAV9 to treat
neurodegenerative diseases would require large vector prepara-
tions to achieve the necessary therapeutic transduction levels in
the CNS (Foust et al., 2009; Gray et al., 2011). Producing the
amount of vector required for a human trial could be challeng-
ing with the current AAV production technology, although the
baculoviral system (Cecchini et al., 2011) has been successfully
used by uniQure to manufacture the ﬁrst licensed gene therapy
product in Europe using an AAV vector, Glybera (Yla-Herttuala,
2012).
Administering such a high titre may result in an adverse
immune response, particularly in those patients that have low
levels of pre-existing AAV antibodies, reducing the efﬁciency
of therapy and increasing the chance of an adverse immune
response (Boutin et al., 2010; Samaranch et al., 2012). Treating
Table 1 | Summary of intravenously administered AAV9-mediated gene delivery studies in perinatal mice and non-human primates.
Species Developmental age
at administration
Promoters Transduction pattern Reference
Mouse E15 Cytomegalovirus
(CMV)
Global transduction of central and peripheral nervous system –
preferential neuronal transduction. Visceral transduction. Rahim et al. (2011)
Mouse PI Chicken-β-actin
hybrid promoter (CB)
CMV
Wide spread delivery to central nervous system – preferential
targeting of neurons or astrocytes. Heart and skeletal muscles. Foust et al. (2009, 2010),
Rahim et al. (2011)
NHP Late gestation (0.9G) CMV Wide spread delivery to the central and peripheral nervous
system – preferential neuronal transduction. Liver, heart, and
skeletal muscles.
Mattar et al. (2013)
NHP PI CB Preferential glial transduction in the brain and neurons in dorsal
root ganglia and motor neurons of spinal cord. Muscle, liver,
Kidney, spleen, heart, lungs, adrenal medulla, intestines, testis.
Bevan et al. (2011)
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younger and, therefore, smaller patients may well overcome any
issue of production and also pre-existing antibodies against AAV9
(although an exclusion criteria in the SMA trial is the presence of
anti-AAV9 antibodies at a titre of >1:50 as determined by ELISA
binding immunoassay). However, high levels of maternal alloan-
tibodies against AAV could trigger an immunization response
through maternal microchimerism that is thought to play a role
in the development of the fetal immune system (Merianos et al.,
2009; Jeanty et al., 2014).
A criticism of perinatal gene therapy is diagnosing a fetus or
neonate early enough for therapeutic intervention. This is depen-
dent upon diagnostic technologies and resources in any given
country, e.g., the availability of prenatal screening and diagnosis
programs. Screening programs even for rare neurological con-
ditions have been established in communities that have a high
prevalence such as Tay–Sachs and GD in the Ashkenazi Jewish
populations (Eng et al., 1997). Advances in ultrasound technology
have led to the ability to identify fetal abnormalities in utero. An
example of this is Niemann–Pick disease type C where although
the severity of disease and age of onset can be highly variable,
fetal presentation in the form of splenomegaly, hepatomegaly, and
ascites are detectable by ultrasound scan (Spiegel et al., 2009). The
continuing development of next generation sequencing (NGS)
over the past decade may ultimately hold the key to early or pre-
term diagnosis. The ability to obtain fetal genetic information
during pregnancy from the mother’s blood has been a long-term
goal. Originally, studies focused on identiﬁcation of such cells
in the maternal circulation. Once cell-free fetal DNA (cffDNA)
was identiﬁed (Lo et al., 1997), the focus directed toward ways of
analyzing such DNA material for prenatal testing. Recently, non-
invasive prenatal diagnosis (NIPD) utilizing cffDNA as early as
7 weeks’ gestation has been introduced into clinical practice as
reviewed by Daley et al. (2014). This approach has been success-
fully used for fetal gender identiﬁcation (Devaney et al., 2011),
a highly accurate screening test for aneuploidies like trisomy 21
(Fan et al., 2008), other major trisomies (Norton et al., 2012),
sex chromosomes abnormalities (Bianchi et al., 2012; Futch et al.,
2013), and the diagnosis of some single gene disorders includ-
ing cystic ﬁbrosis, thalassaemia, and achondroplasia (Lench et al.,
2013).
A more reliable, sensitive and cost effective method for NIPD in
monogenic disorders is provided byNGSplatforms. Now available
in routine diagnostic laboratories, they can accurately quantify
certain sequences in the maternal blood. An example was for the
identiﬁcation of Down Syndrome by whole genome sequencing
by quantifying cffDNA sequences mapping to chromosome 21
(Fan et al., 2008). A more recent application of NGS in NIPD for
b-thalassemia has been described (Lam et al., 2012).
Next generation sequencing presents many advantages over
standard PCR-based genetic testing. The high throughput of NGS
allows samples from different patients to be multiplexed in a single
run. This combined with the ability to design assays with multiple
mutations inmultiple genes tobe included in a single test are allow-
ing a reduced cost per sample as well as a quick turn-around-time
Table 2 | Summary of using AAV in perinatal gene therapy and its clinical implication.
AAV transduction efficiency
• The ability of AAV serotypes to cross the BBB highlights its systemic transduction capabilities.
• Intravenous administration of AAV9 at either fetal or neonatal stage of development in rodents and NHP targets different cell types within the
nervous system; neurons via fetal intravenous (iv) and astrocytes and microglia via neonatal iv administration.
• The iv approach is ideal for systemic neurodegenerative disorders.
Advantages of perinatal gene delivery
• Efﬁcient gene delivery is achieved due to; large vector to cell ratio, induction of immune-tolerance (at least in rodents) to foreign protein expression.
• Ideal for early lethal neurodegenerative diseases as it allows for therapeutic transduction of cells and organs prior to disease pathology
manifestation.
Potential disadvantages of perinatal gene therapy
• Lack of diagnostic technologies or infrastructure to identify disease in patients early enough.
• In utero ultrasound or exposed surgical procedure may impose risk such as fetal loss or preterm birth.
• Over expression of the therapeutic transgene in the fetus may cause developmental abnormalities.
• Fetal iv preferentially targets neurons and not astrocytes.
Clinical implication
• Perinatal gene therapy has been successful in a number of animal CNS diseases.
• Intravenous route of administration is favorable for its ability to cross the BBB and target other peripheral organs.
• Particular AAV serotypes ability to cross the BBB provides and alternative to intracranial administration which would require surgery and its
attendant risks.
• Successful clinical trials have taken place where systemic delivery of AAV and disease speciﬁc transgene has been delivered topically and
intravenously to patients.
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for reporting results. With the cost of NGS constantly decreasing
and the imminent implementation of whole exome sequencing
(which allows the simultaneous sequence of all coding exons) in
diagnostic laboratories, NGS and NIPD will be increasingly used
for the diagnosis of a range of monogenic disorders (Lench et al.,
2013). Although the cost is still high and the time of data analysis
long, whole genome sequencing could be implemented to proﬁle
the entire fetal genomes (Lo et al., 2010).
CONCLUDING REMARKS
Perinatal gene therapy has distinct advantages (Summarized in
Table 2) and is essential in addressing those diseases that mani-
fest during the neonatal stage or even in utero. This is particularly
important in early lethal neurodegenerative disorders where vul-
nerable post-mitotic neuronsmust be rescued or risk irrecoverable
loss. The presence of additional systemic pathology is a further
complication. However, the potential of intravenously adminis-
tered AAV to provide systemic gene therapy is highly attractive in
treating such pleiotropic conditions. Of course, there are signiﬁ-
cant practical issues that need to be overcome for perinatal gene
therapy to be realized in the clinic. However, we are moving in the
right direction with advances in prenatal diagnostic technologies,
clinical trials demonstrating that intravenously administered AAV
vectors are safe and plans to take this further in young children
with SMA. The ascendancy of gene therapy through a num-
ber of recent successful gene therapy trials (Gaspar et al., 2004;
Bainbridge et al., 2008; Cartier et al., 2009; Nathwani et al., 2011;
Aiuti et al., 2013; Bifﬁ et al., 2013) and the approval of the ﬁrst
gene therapy product to be sold in Europe (Yla-Herttuala, 2012)
has meant that the ﬁeld in general is gathering momentum and
is an opportune moment to bring systemic perinatal gene therapy
into the limelight.
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